Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
11794results about "Peptides" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
PendingUS20060104968A1Improve extentIncrease ratingsSenses disorderNervous disorderHyaluronidaseRecombinant glycoprotein
The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
Owner:HALOZYME
Delivery and formulation of engineered nucleic acids
ActiveUS20120251618A1Improve the level ofIncrease in level of polypeptideNervous disorderAntipyreticNucleic acidProtein expression
Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.
Owner:MODERNATX INC
Corn Plant and Seed Corresponding to Transgenic Event MON89034 and Methods For Detection and Use Thereof
ActiveUS20080260932A1Microbiological testing/measurementClimate change adaptationNucleotideNucleotide sequencing
The present invention provides a transgenic corn event MON89034, and cells, seeds, and plants comprising DNA diagnostic for the corn event. The invention also provides compositions comprising nucleotide sequences that are diagnostic for said corn event in a sample, methods for detecting the presence of said corn event nucleotide sequences in a sample, probes and primers for use in detecting nucleotide sequences that are diagnostic for the presence of said corn event in a sample, growing the seeds of such corn event into corn plants, and breeding to produce corn plants comprising DNA diagnostic for the corn event.
Owner:MONSANTO TECH LLC
Synthetic genes encoding cry1ac
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions containing a synthetic nucleotide sequence encoding a Cry1Ac protein are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also include transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated pesticidal nucleic acid molecules are provided, wherein the nucleotide sequences are set forth in SEQ ID NO:1, 2, 3, 4, 5 or 6, as well as variants and fragments thereof.
Owner:ATHENIX
Modified fluorinated nucleoside analogues
ActiveUS20050009737A1Strong specificityLow toxicityAntibacterial agentsBiocideRhinovirus infectionWest Nile virus RNA
The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.
Owner:GILEAD SCI INC
Axmi-028 and axmi-029, a family of novel delta-endotoxin genes and methods for their use
Owner:BASF AGRICULTURAL SOLUTIONS SEED LLC
Axmi-028 and axmi-029, a family of novel delta-endotoxin genes and methods for their use
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:2, 4, 15, 17, or 19, or the nucleotide sequence set forth in SEQ ID NO:1, 3, 14, 16, or 18, as well as variants and fragments thereof.
Owner:BASF AGRICULTURAL SOLUTIONS SEED LLC
Imide-based modulators of proteolysis and associated methods of use
The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and / or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation / inhibition of targeted polypeptides of nearly any type.
Owner:ARVINAS OPERATIONS INC
Promoter sequences from Corynebacterium ammoniagenes
Owner:CJ CHEILJEDANG CORP
Small molecule toll-like receptor (TLR) antagonists
The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core structure including at least two rings. Certain of the compounds are 4-primary amino quinolines. Many of the compounds and methods are useful specifically for inhibiting immune stimulation involving at least one of TLR9, TLR8, TLR7, and TLR3. The methods may have use in the treatment of autoimmunity, inflammation, allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer, and immunodeficiency.
Owner:COLEY PHARMA GMBH +1
Promoter and uses thereof
Owner:CJ CHEILJEDANG CORP
Methods for genetic control of insect infestations in plants and compositions thereof
ActiveUS20070124836A1Inhibit expressionReduced expression levelSugar derivativesClimate change adaptationBiotechnologyDouble strand
The present invention relates to control of pest infestation by inhibiting one or more biological functions. The invention provides methods and compositions for such control. By feeding one or more recombinant double stranded RNA molecules provided by the invention to the pest, a reduction in pest infestation is obtained through suppression of gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, and to particular combinations of transgenic pesticidal agents for use in protecting plants from pest infestation.
Owner:MONSANTO TECH LLC
Prodrugs built as multiple self-elimination-release spacers
This invention concerns multiple release spacers and spacer systems, which release multiple leaving groups following a single activation. It concerns compounds comprising a specifier linked to two or more of the same or different leaving groups (L in the figure) via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release at least two leaving groups.
Owner:SYNTARGA BV
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
ActiveUS20130115272A1Reduce innate immune responseBiocidePeptide/protein ingredientsNucleotideModified nucleosides
The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.
Owner:MODERNATX INC
Modified nucleoside, nucleotide, and nucleic acid compositions
InactiveUS20130156849A1Therapeutically effectiveRaise hemoglobinOrganic active ingredientsPowder deliveryProtein precursorNucleotide
The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and / or activity.
Owner:MODERNA THERAPEUTICS INC
Device and method for pressure-driven plug transport and reaction
ActiveUS20050087122A1Eliminate evaporationWell mixedMaterial nanotechnologySequential/parallel process reactionsPressure.driveCarrier fluid
Owner:UNIVERSITY OF CHICAGO
Nuclear reprogramming factor and induced pluripotent stem cells
InactiveUS20090227032A1Easy to prepareEffective isolationGenetically modified cellsPeptidesNuclear reprogrammingCell therapy
The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including screening and testing methods as well as methods of stem cell therapy. The present invention also relates to somatic cells derived by inducing differentiation of the aforementioned iPS cells.
Owner:KYOTO UNIV
Cytotoxic compounds and conjugates
Owner:ER SQUIBB & SONS INC
Chemical modifications of monomers and oligonucleotides with cycloaddition
The invention features compounds of formula I or II:In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.
Owner:ALNYLAM PHARMA INC
PUFA polyketide synthase systems and uses thereof
The invention generally relates to polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems, to homologues thereof, to isolated nucleic acid molecules and recombinant nucleic acid molecules encoding biologically active domains of such a PUFA PKS system, to genetically modified organisms comprising PUFA PKS systems, to methods of making and using such systems for the production of bioactive molecules of interest, and to novel methods for identifying new bacterial and non-bacterial microorganisms having such a PUFA PKS system.
Owner:DSM IP ASSETS BV
Hepatitis C virus inhibitors
ActiveUS7041698B2Inhibit functioningEffective treatmentBiocideTetrapeptide ingredientsHcv hepatitis c virusPharmaceutical drug
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
Owner:BRISTOL MYERS SQUIBB CO
IAP binding compounds
InactiveUS20060025347A1Reduce and eliminate cellular proliferation disorderBiocideNervous disorderInhibitor of apoptosisApoptosis
IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.
Owner:MEDIVIR AB
Methods for genetic control of insect infestations in plants and compositions thereof
ActiveUS7943819B2Reduced expression levelLow effective doseSugar derivativesClimate change adaptationGMO PlantsDouble stranded rna
Owner:MONSANTO TECH LLC
Helically organized silk fibroin fiber bundles for matrices in tissue engineering
InactiveUS6902932B2Immobilised enzymesBioreactor/fermenter combinationsFiber bundleLigament structure
The present invention provides a novel silk-fiber-based matrix having a wire-rope geometry for use in producing a ligament or tendon, particularly an anterior cruciate ligament, ex vivo for implantation into a recipient in need thereof. The invention further provides the novel silk-fiber-based matrix which is seeded with pluripotent cells that proliferate and differentiate on the matrix to form a ligament or tendon ex vivo. Also disclosed is a bioengineered ligament comprising the silk-fiber-based matrix seeded with pluripotent cells that proliferate and differentiate on the matrix to form the ligament or tendon. A method for producing a ligament or tendon ex vivo comprising the novel silk-fiber-based matrix is also disclosed.
Owner:ALLERGAN INC +1
Biopolymer optical waveguide and method of manufacturing the same
ActiveUS20100063404A1Minimize negative impactImprove functional propertiesBiological material analysisMonocomponent fibroin artificial filamentFiberBiopolymer
A method of manufacturing a biopolymer optical waveguide includes providing a biopolymer, unwinding the biopolymer progressively to extract individual biopolymer fibers, and putting the unwound fibers under tension. The tensioned fibers are then cast in a different polymer to form a biopolymer optical waveguide that guides light due to the difference in indices of refraction between the biopolymer and the different polymer. The optical fibers may be used in biomedical applications and can be inserted in the body as transmissive media. Printing techniques may be used to manufacture the biopolymer optical waveguides.
Owner:TRUSTEES OF TUFTS COLLEGE
Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
ActiveUS8129187B2Easy to prepareEffective isolationGenetically modified cellsArtificial cell constructsNuclear reprogrammingCell therapy
Owner:KYOTO UNIV
Device and method for pressure-driven plug transport and reaction
InactiveUS20100233026A1Well mixedQuick mixMaterial nanotechnologySequential/parallel process reactionsPressure.driveCarrier fluid
Owner:ISMAGLIOV RUSTEM F +3
Dimeric small molecule potentiators of apoptosis
Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of the dimeric mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com